Abstract 3037
Background
Immunotherapy (IO) is an established treatment (tx) option for metastatic non-small cell lung cancer (mNSCLC). Nonetheless, as only a minority of pts shows tumor response, research is focusing on identification of predictive factors to improve pts’ selection. The potential role of blood cell count alterations has been proposed, but evidence is contradictory. We aimed at studying the role of lymphopenia in a cohort of mNSCLC pts treated with IO.
Methods
We retrospectively collected data about all mNSCLC pts treated with IO at Istituto Nazionale dei Tumori, Milan, Italy, from 04/2013 to 01/2018. Basal lymphopenia (Lp) was defined as a lymphocyte count (LC)≤900/mL at the first administration of IO and was considered as a categorical variable. Survival was estimated with Kaplan-Meier method; log-rank test was used to compare curves. Multivariate analyses were performed with Cox proportional model.
Results
We identified 150 pts, with a median age of 66.5 years. IO was an antiPD1 in 64.0% of cases, an antiPDL1 in 31.3% of cases, and a combination antiPDL1/CTLA4 in 4.7% of cases. IO was administered as a first line tx in 23 pts, as a second line tx in 66 cases, as a more advanced line of tx in 61 cases. Median progression free survival (PFS) and overall survival (OS) of the global population were 3.2 and 11.2 months (mos), respectively. Though non-statistically significant, there was a tendency towards a lower response rate (RR) for cases with basal Lp (10.0% vs 25.0%, p.0881); disease control rate (DCR) for the same group was significantly worse (30.0% vs 58.4%, p.0074) than for cases without Lp. Pts with Lp also showed shorter PFS and OS than cases with normal LC (PFS 1.9 vs 3.0 mos, p.0010; OS 4.5 vs 13.5 mos, p<.0001). The impact of LC on OS retained significance after correction for the effects of performance status, which was the only other variable influencing this endpoint.
Conclusions
The presence of Lp at the beginning of IO was related to inferior disease control and shorter survival in the analyzed cohort. Given the limitations of a retrospective study, these results need confirmation in larger case series. Nonetheless, the suggestion that Lp may predict poor benefit from IO in mNSCLC warrants further investigation.
Clinical trial identification
Legal entity responsible for the study
Istituto Nazionale dei Tumori.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
G. Lo Russo: Honoraria: Eli Lilly, BMS, AstraZeneca. C. Proto: Honoraria: BMS, MSD, Eli Lilly. D. Signorelli: Honoraria: AstraZeneca, Boehringer Ingelheim, BMS. M.C. Garassino: Honoraria: Boehringer Ingelheim, AstraZeneca, Roche. M. Imbimbo: Honoraria: BMS. All other authors have declared no conflicts of interest.
Resources from the same session
5964 - Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence
Presenter: Karin Birkenkamp-Demtröder
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2197 - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas
Presenter: Evgeny Imyanitov
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2422 - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: independent actors or reciprocal drivers? A translational study by Meet-Uro group
Presenter: Marzia Del Re
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2750 - Validation of a 90-gene assay for tissue origin diagnosis of brain metastases
Presenter: Yulong Zheng
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2960 - Development of a Pan-Cancer Biomarker Panel for Improved Detection of MSI Across all Cancer Types
Presenter: Jeff Bacher
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3791 - bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients
Presenter: Zhenghang Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5189 - Vall d’Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).
Presenter: Cinta Hierro
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5372 - Augmenting TNM Staging with Machine Learning-based Immune Profiling for Improved Prognosis Prediction in Muscle-Invasive Bladder Cancer Patients
Presenter: Nicolas Brieu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2249 - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma
Presenter: Alice Bernard-Tessier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2287 - Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis
Presenter: Marco Iafolla
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract